- United Kingdom
- /
- Biotech
- /
- LSE:GNS
Exploring Three High Growth Tech Stocks in the United Kingdom
Reviewed by Simply Wall St
Amidst the recent challenges in the UK market, highlighted by a faltering FTSE 100 due to weak trade data from China and declining commodity prices impacting key sectors, investors are keenly observing how these economic shifts influence high-growth opportunities. In such a climate, identifying tech stocks with strong fundamentals and innovative potential becomes crucial for navigating uncertainties and capturing growth prospects.
Top 10 High Growth Tech Companies In The United Kingdom
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
STV Group | 13.15% | 46.78% | ★★★★★☆ |
Facilities by ADF | 48.47% | 189.97% | ★★★★★☆ |
Redcentric | 5.32% | 67.90% | ★★★★★☆ |
Windar Photonics | 79.38% | 195.81% | ★★★★★☆ |
Beeks Financial Cloud Group | 22.12% | 36.94% | ★★★★★☆ |
Seeing Machines | 21.40% | 97.67% | ★★★★★☆ |
Oxford Biomedica | 21.20% | 92.53% | ★★★★★☆ |
YouGov | 8.52% | 55.02% | ★★★★★☆ |
Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 49 stocks from our UK High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Craneware (AIM:CRW)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Craneware plc, along with its subsidiaries, focuses on developing, licensing, and supporting computer software tailored for the healthcare industry in the United States and has a market capitalization of £840.43 million.
Operations: The company generates revenue primarily from its healthcare software segment, which amounts to $189.27 million.
Craneware, a UK-based tech firm, is demonstrating robust growth in the healthcare technology sector. With its recent strategic partnership with Microsoft Azure, Craneware is enhancing its cloud-based solutions for U.S. healthcare providers, which could significantly amplify operational efficiency and financial performance analytics through AI integration. Financially, the company's revenue growth forecast at 8.1% per year outpaces the UK market average of 3.6%, while anticipated earnings growth stands at an impressive 24.3% annually. This performance is underpinned by a solid track record of high-quality past earnings and a commitment to innovation as evidenced by their participation in multiple industry conferences and continuous product development on the Azure platform.
- Delve into the full analysis health report here for a deeper understanding of Craneware.
Examine Craneware's past performance report to understand how it has performed in the past.
LBG Media (AIM:LBG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: LBG Media plc is an online media publisher with operations in the United Kingdom, Ireland, Australia, the United States, and internationally, and has a market cap of £248.80 million.
Operations: LBG Media generates revenue primarily from its online media publishing activities, amounting to £82.54 million. The company operates across multiple regions, including the UK, Ireland, Australia, and the US.
LBG Media, amidst a transformative phase, reported a substantial revenue increase to GBP 42.28 million from GBP 27.25 million year-over-year as of June 2024, marking a pivotal rebound with net income swinging to GBP 4.75 million from a previous loss of GBP 1.8 million. This financial revitalization is supported by an impressive forecasted annual earnings growth rate of 24.5%, significantly outpacing the UK market's average growth expectations. The company's commitment to innovation is evident in its R&D investments, crucial for sustaining its competitive edge in the dynamic tech landscape. Moreover, LBG's strategic focus on enhancing user engagement and content quality has catalyzed its above-market revenue growth rate of 9.6%. This approach not only underscores its adaptability within the tech sector but also aligns with broader industry trends towards personalized digital experiences. Looking ahead, LBG Media appears poised for continued growth, leveraging robust operational strategies and ongoing market expansions to potentially outperform sector averages and enrich shareholder value over the coming years.
- Navigate through the intricacies of LBG Media with our comprehensive health report here.
Explore historical data to track LBG Media's performance over time in our Past section.
Genus (LSE:GNS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Genus plc is an animal genetics company with a market cap of £1.09 billion, operating across North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia.
Operations: Genus plc generates revenue primarily from its Genus ABS and Genus PIC segments, contributing £314.90 million and £352.50 million respectively. The company operates in various regions including North America, Latin America, Europe, Asia, and more.
Amidst a landscape of rapid technological evolution, Genus plc stands out with its robust R&D commitment, earmarking substantial resources to foster innovation. In the fiscal year ending June 2024, the company allocated £47.8 million to research and development, reflecting an assertive strategy to secure a competitive edge in biotechnology. This investment is pivotal as Genus aims to navigate through recent challenges including a significant one-off loss that impacted earnings. However, looking forward, the company's revenue is expected to grow by 4% annually, outpacing the UK market's growth rate of 3.6%. Additionally, recent executive changes and reaffirmed dividends signal ongoing strategic adjustments and confidence in future financial health. With these elements combined—strong R&D focus coupled with strategic leadership transitions—Genus is poised to harness growth opportunities within the high-tech biotech sector while enhancing shareholder value.
- Take a closer look at Genus' potential here in our health report.
Gain insights into Genus' past trends and performance with our Past report.
Make It Happen
- Unlock our comprehensive list of 49 UK High Growth Tech and AI Stocks by clicking here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About LSE:GNS
Genus
Operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.
Reasonable growth potential and slightly overvalued.